• About
  • Subscribe
  • Advertise
  • Contact
Monday, December 15, 2025
Newsletter
SUBSCRIBE
  • Latest News
  • All Sections
    • Ophthalmic insights
      • Policy & regulation
      • Company updates & acquisitions
      • Research
      • Clinical trials
      • Workforce
      • Product approvals
      • Conferences
      • Opinion
      • Indigenous eye health
      • Retail
    • Eye disease
      • Dry eye
      • Myopia
      • Cataract
      • Glaucoma
      • Macular disease – AMD
      • Diabetic eye disease
      • Inherited retinal disease
      • Corneal disease
      • Presbyopia
      • Eye infections
    • Ophthalmic Careers
      • New appointments
      • Industry profiles
      • Graduates
    • Ophthalmic organisations
      • Regulators
      • Optometry networks
      • Private ophthalmology clinics
      • Associations
      • Patient support bodies
      • Eye research institutions
      • Optometry schools
      • Optical Dispensing trainers
      • Medical schools
      • RANZCO
  • Features
    • Report
    • Soapbox
  • Ophthalmic education
    • CPD – Optometry
    • Optical Dispensing
    • Orthoptics Australia
    • Practice management
  • Products
    • Ophthalmic Treatments
      • Ophthalmic lenses
      • Lens treatments
      • Myopia interventions
      • Light-based therapy
      • Minimally invasive glaucoma surgery (MIGS)
      • Gene therapy
      • Laser treatments
      • Supplements
      • Eyewear & frames
      • Behavioural optometry/vision training
      • Contact lenses
      • Anti-VEGF
      • Intraocular lenses (IOLs)
      • Pharmaceuticals & consumables
    • Ophthalmic equipment & diagnostics
      • Biometry – axial length
      • Perimetry & visual fields
      • OCT
      • Phoropter
      • Autorefractor
      • Tonometry
      • Topography
      • Multimodal imaging
      • Retinal imaging
      • Anterior segment imaging
      • Software & data management
      • Microscopes
      • Slit lamps
      • Lens edging
      • Stands, chairs and tables
      • Ultrasound
      • Dry eye diagnostics
      • Low vision aids
  • Research
  • Classifieds
No Results
View All Results
  • Latest News
  • All Sections
    • Ophthalmic insights
      • Policy & regulation
      • Company updates & acquisitions
      • Research
      • Clinical trials
      • Workforce
      • Product approvals
      • Conferences
      • Opinion
      • Indigenous eye health
      • Retail
    • Eye disease
      • Dry eye
      • Myopia
      • Cataract
      • Glaucoma
      • Macular disease – AMD
      • Diabetic eye disease
      • Inherited retinal disease
      • Corneal disease
      • Presbyopia
      • Eye infections
    • Ophthalmic Careers
      • New appointments
      • Industry profiles
      • Graduates
    • Ophthalmic organisations
      • Regulators
      • Optometry networks
      • Private ophthalmology clinics
      • Associations
      • Patient support bodies
      • Eye research institutions
      • Optometry schools
      • Optical Dispensing trainers
      • Medical schools
      • RANZCO
  • Features
    • Report
    • Soapbox
  • Ophthalmic education
    • CPD – Optometry
    • Optical Dispensing
    • Orthoptics Australia
    • Practice management
  • Products
    • Ophthalmic Treatments
      • Ophthalmic lenses
      • Lens treatments
      • Myopia interventions
      • Light-based therapy
      • Minimally invasive glaucoma surgery (MIGS)
      • Gene therapy
      • Laser treatments
      • Supplements
      • Eyewear & frames
      • Behavioural optometry/vision training
      • Contact lenses
      • Anti-VEGF
      • Intraocular lenses (IOLs)
      • Pharmaceuticals & consumables
    • Ophthalmic equipment & diagnostics
      • Biometry – axial length
      • Perimetry & visual fields
      • OCT
      • Phoropter
      • Autorefractor
      • Tonometry
      • Topography
      • Multimodal imaging
      • Retinal imaging
      • Anterior segment imaging
      • Software & data management
      • Microscopes
      • Slit lamps
      • Lens edging
      • Stands, chairs and tables
      • Ultrasound
      • Dry eye diagnostics
      • Low vision aids
  • Research
  • Classifieds
No Results
View All Results
Home Company updates & acquisitions

EssilorLuxottica secures final GrandVision clearance; unveils sustainable acetate plans

by Staff Writer
June 15, 2021
in Business, Company updates & acquisitions, International, News
Reading Time: 2 mins read
A A
Essilorluxottica sustainability

Essilorluxottica sustainability

Share on FacebookShare on Twitter

The Turkish Competition Authority has cleared EssilorLuxottica’s GrandVision takeover. It’s the final country to approve the deal, but it won’t be finalised until arbitration proceedings are ironed out between the two companies.

It comes as Luxottica also announced a stake in Italian eyewear materials producer Mazzucchelli to develop and manufacture “a highly sustainable type of acetate” that it plans to release to the wider optical market.

On 10 June, the Turkish government approved the GrandVision deal after EssilorLuxottica “made certain behavioural commitments” regarding the conduct of its business in the country.

Turkey was the last jurisdiction to consider the deal, which had previously been approved in the US, Russia, Colombia, Brazil, Chile and Mexico. The European Commission cleared the acquisition on 23 March on the condition that around 350 stores are divested across Belgium, the Netherlands and Italy.

Once finalised, EssilorLuxottica will acquire a 76.7% stake in GrandVision that is currently owned by Dutch investment firm HAL. Valued by financial analysts to be worth €7.2 billion (AU$11.2 billion), it’s expected to see EssilorLuxottica drastically increase its footprint by around 7,000 stores and 37,000 employees across 40 countries.

However, the outcome of the transaction is still subject to the outcome of ongoing arbitration proceedings between the entities. The legal saga was sparked by EssilorLuxottica which was concerned about how GrandVision managed its business during the COVID-19 crisis.

In the latest development, GrandVision has requested an arbitral tribunal to confirm among other things, that it was is not in material breach of its agreement with EssilorLuxottica. HAL has also initiated proceedings.

“These proceedings are confidential. A decision … is expected in the second half of June 2021,” a GrandVision statement said.

Sustainable acetate

Meanwhile, Luxottica’s new deal with Mazzucchelli – a worldwide leader in the manufacture and distribution of cellulose acetate sheets – will see it take a minority 35% stake in the firm.

This will allow Mazzucchelli, based in the Lombardy region, to advance the manufacture of a sustainable acetate within its production plants.

“The transaction confirms and strengthens the long-standing commitment of Luxottica, which is part of the EssilorLuxottica Group, and Mazzucchelli to reduce the environmental impact of their activities in the long term along the value chain, increasing the offer of high quality and sustainable eyewear,” Luxottica stated.

More reading

European Commission clears EssilorLuxottica’s GrandVision takeover

EssilorLuxottica and GrandVision deal hits stumbling block

EssilorLuxottica weighs up appeal after GrandVision case dismissed

Tags: AcquisitionauthoritiescompetitionEssilorLuxotticaeyewearFramesgovernmentGrandVisionLuxotticaMazzucchelliSustainable acetatetakeoverTurkey

Related Posts

This image shows a retinal detachment captured on Silverstone RGB with true colour optomap ultra-widefield imaging (left) and SS-OCT (right). Image: Optos.

Seeing in true colour with Optos

by Rob Mitchell
December 13, 2025

Silverstone RGB is Optos’ first ultra-widefield system combining red, green and blue laser channels with swept source OCT, giving clinicians...

Globally, more than 196 million people have AMD. Image: Jum/stock.adobe.com.

Aussie study pinpoints key genetic changes in AMD risk

by Staff Writer
December 12, 2025

Australian researchers have for the first time pinpointed specific genetic changes that increase the risk of severe, sight-threatening forms of...

Almost 90% of medical trainees have rated their training highly in the latest MTS. Image: Ai design/stock.adobe.com.

Medical trainees point to unacceptable behaviour in health system

by Staff Writer
December 12, 2025

Medical trainees have rated the quality of their medical training highly in the latest Medical Training Survey, but the rate...

Join our newsletter

View our privacy policy, collection notice and terms and conditions to understand how we use your personal information.

Insight has been the leading industry publication in Australia for more than 40 years. This longevity is largely due to our ability to consistently deliver accurate and independent news relevant to all ophthalmic professionals and their supporting industry.

Subscribe to our newsletter

View our privacy policy, collection notice and terms and conditions to understand how we use your personal information.

About Insight

  • About
  • Advertise
  • Subscribe
  • Contact
  • Terms & Conditions
  • Privacy Collection Notice
  • Privacy Policy

Popular Topics

  • Business
  • Feature
  • Research
  • Technology
  • Therapies
  • Classifieds

© 2025 All Rights Reserved. All content published on this site is the property of Prime Creative Media. Unauthorised reproduction is prohibited

No Results
View All Results
NEWSLETTER
SUBSCRIBE
  • Latest News
  • All Sections
    • Ophthalmic insights
      • Policy & regulation
      • Company updates & acquisitions
      • Research
      • Clinical trials
      • Workforce
      • Product approvals
      • Conferences
      • Opinion
      • Indigenous eye health
      • Retail
    • Eye disease
      • Dry eye
      • Myopia
      • Cataract
      • Glaucoma
      • Macular disease – AMD
      • Diabetic eye disease
      • Inherited retinal disease
      • Corneal disease
      • Presbyopia
      • Eye infections
    • Ophthalmic Careers
      • New appointments
      • Industry profiles
      • Graduates
    • Ophthalmic organisations
      • Regulators
      • Optometry networks
      • Private ophthalmology clinics
      • Associations
      • Patient support bodies
      • Eye research institutions
      • Optometry schools
      • Optical Dispensing trainers
      • Medical schools
      • RANZCO
  • Features
    • Report
    • Soapbox
  • Ophthalmic education
    • CPD – Optometry
    • Optical Dispensing
    • Orthoptics Australia
    • Practice management
  • Products
    • Ophthalmic Treatments
      • Ophthalmic lenses
      • Lens treatments
      • Myopia interventions
      • Light-based therapy
      • Minimally invasive glaucoma surgery (MIGS)
      • Gene therapy
      • Laser treatments
      • Supplements
      • Eyewear & frames
      • Behavioural optometry/vision training
      • Contact lenses
      • Anti-VEGF
      • Intraocular lenses (IOLs)
      • Pharmaceuticals & consumables
    • Ophthalmic equipment & diagnostics
      • Biometry – axial length
      • Perimetry & visual fields
      • OCT
      • Phoropter
      • Autorefractor
      • Tonometry
      • Topography
      • Multimodal imaging
      • Retinal imaging
      • Anterior segment imaging
      • Software & data management
      • Microscopes
      • Slit lamps
      • Lens edging
      • Stands, chairs and tables
      • Ultrasound
      • Dry eye diagnostics
      • Low vision aids
  • Research
  • Classifieds
  • About Us
  • Advertise with Insight
  • Subscribe
  • Contact Insight

© 2025 All Rights Reserved. All content published on this site is the property of Prime Creative Media. Unauthorised reproduction is prohibited